Systemic Lupus Erythematosus Archives - MPR

Systemic Lupus Erythematosus

Anifrolumab Effectively Reduced Disease Activity for Lupus Patients in Phase 3 Trial

AstraZeneca has announced positive topline data from the phase 3 TULIP 2 trial of anifrolumab for the treatment of systemic lupus erythematosus (SLE). Anifrolumab is a fully human monoclonal antibody that binds to subunit 1 of the type I interferon (IFN) receptor and blocking all type I IFNs including IFN-alpha, IFN-beta and IFN-omega. The TULIP…